These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Gene therapy and angiogenesis in patients with coronary artery disease. Kastrup J Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1127-38. PubMed ID: 20670190 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Sellke FW; Laham RJ; Edelman ER; Pearlman JD; Simons M Ann Thorac Surg; 1998 Jun; 65(6):1540-4. PubMed ID: 9647055 [TBL] [Abstract][Full Text] [Related]
7. The value of angiogenic therapy with intramyocardial administration of basic fibroblast growth factor to treat severe coronary artery disease. Katayama Y; Takaji K; Shao ZQ; Matsukawa M; Kunitomo R; Hagiwara S; Moriyama S; Kawasuji M Ann Thorac Cardiovasc Surg; 2010 Jun; 16(3):174-80. PubMed ID: 20930678 [TBL] [Abstract][Full Text] [Related]
8. Intramyocardial injection of low-dose basic fibroblast growth factor or vascular endothelial growth factor induces angiogenesis in the infarcted rabbit myocardium. Bougioukas I; Didilis V; Ypsilantis P; Giatromanolaki A; Sivridis E; Lialiaris T; Mikroulis D; Simopoulos C; Bougioukas G Cardiovasc Pathol; 2007; 16(2):63-8. PubMed ID: 17317537 [TBL] [Abstract][Full Text] [Related]
9. Effects of L-arginine on the endogenous angiogenic response in a model of hypercholesterolemia. Nakai Y; Voisine P; Bianchi C; Xu SH; Feng J; Malik T; Rosinberg A; Sellke FW Surgery; 2005 Aug; 138(2):291-8. PubMed ID: 16153439 [TBL] [Abstract][Full Text] [Related]
10. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Voisine P; Li J; Bianchi C; Khan TA; Ruel M; Xu SH; Feng J; Rosinberg A; Malik T; Nakai Y; Sellke FW Circulation; 2005 Aug; 112(9 Suppl):I202-7. PubMed ID: 16159817 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Ruel M; Wu GF; Khan TA; Voisine P; Bianchi C; Li J; Li J; Laham RJ; Sellke FW Circulation; 2003 Sep; 108 Suppl 1():II335-40. PubMed ID: 12970256 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic angiogenesis as a new experimental treatment for vascular disease]. Lucassen AM; de Waal RM; Verheugt FW Ned Tijdschr Geneeskd; 2000 Apr; 144(14):650-5. PubMed ID: 10774292 [TBL] [Abstract][Full Text] [Related]
13. Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Chang PY; Chen YJ; Chang FH; Lu J; Huang WH; Yang TC; Lee YT; Chang SF; Lu SC; Chen CH Cardiovasc Res; 2013 Jul; 99(1):137-45. PubMed ID: 23519265 [TBL] [Abstract][Full Text] [Related]
14. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. Laham RJ; Rezaee M; Post M; Novicki D; Sellke FW; Pearlman JD; Simons M; Hung D J Pharmacol Exp Ther; 2000 Feb; 292(2):795-802. PubMed ID: 10640320 [TBL] [Abstract][Full Text] [Related]
15. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardium for the treatment of ischemic heart disease. Yokoyama S; Fukuda N; Li Y; Hagikura K; Takayama T; Kunimoto S; Honye J; Saito S; Wada M; Satomi A; Kato M; Mugishima H; Kusumi Y; Mitsumata M; Murohara T J Mol Cell Cardiol; 2006 Jan; 40(1):24-34. PubMed ID: 16271723 [TBL] [Abstract][Full Text] [Related]
16. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Banquet S; Gomez E; Nicol L; Edwards-Lévy F; Henry JP; Cao R; Schapman D; Dautreaux B; Lallemand F; Bauer F; Cao Y; Thuillez C; Mulder P; Richard V; Brakenhielm E Circulation; 2011 Aug; 124(9):1059-69. PubMed ID: 21824923 [TBL] [Abstract][Full Text] [Related]
17. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Davis FB; Mousa SA; O'Connor L; Mohamed S; Lin HY; Cao HJ; Davis PJ Circ Res; 2004 Jun; 94(11):1500-6. PubMed ID: 15117822 [TBL] [Abstract][Full Text] [Related]
18. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562 [TBL] [Abstract][Full Text] [Related]
19. Delivery of basic fibroblast growth factor using heparin-conjugated fibrin for therapeutic angiogenesis. Yang HS; Bhang SH; Hwang JW; Kim DI; Kim BS Tissue Eng Part A; 2010 Jun; 16(6):2113-9. PubMed ID: 20136400 [TBL] [Abstract][Full Text] [Related]
20. The future of therapeutic myocardial angiogenesis. Boodhwani M; Sodha NR; Laham RJ; Sellke FW Shock; 2006 Oct; 26(4):332-41. PubMed ID: 16980878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]